available to support its use in any subset of patients, and no organizational or society guidelines endorse this approach. In general, virtually all experts agree that candidate patients should have no visceral meta stases. If induction ADT is employed, PSA nadir should be low after systemic therapy with ADT or next-generation antiandrogens. Despite the lack of guidelines, consensus, or level I evidence, the need for a treatment protocol in these patients is growing, as oligometa static disease is increasingly identified with novel PET imaging techniques using prostatespecific membrane antigen (PMSA), 18 F-NaF, 11 C-Choline, 18 F-Choline, or 18 F-Fluciclovine tracers. The pressure to offer this aggressive approach is increasing, especially for otherwise healthy and young patients who would benefit from the longer survival associated with this treatment option. However, how to proceed while we await completed controlled trials is unclear. In our practice, we have a robust multidisciplinary team approach 8 and, as a surgeon, will only make the decision to perform radical prostatectomy in a man with documented M1 disease after the patient has seen both a genitourinary medical oncologist and a radiation oncologist and after the patient is vetted for therapy by our tumour board.
Ultimately, randomized controlled trials (RCTs) are needed to answer this important question and results are on the horizon, with >10 trials underway worldwide 1 . In February 2018, Ost and colleagues 9 reported data from a phase II RCT of 62 patients with biochemical recurrence of their prostate cancer who had ≤3 metastases detected on choline PET scans, comparing outcomes after observation or metastases-directed radiotherapy. At a mean follow-up duration of 3 years, time to ADT initiation was delayed in patients who had metastasis-directed therapy compared with those who were observed. Although this study is a first step for published RCTs in this field, this RCT was very preliminary and included very few patients.
Overall, Dall'Era and co-workers are to be congratulated for tackling a very hot topic. Only time will tell if men with oligometastatic prostate cancer will glean long-term benefit from treatment of local disease. Androgen ablation therapy has been the corner stone of initial treatment for metastatic prostate cancer for decades, based on Huggins and Hodges' 1941 finding that androgens drive prostate carcinogenesis 1 . In the early 1990s, it was hypothesized that inhibition of 5α-reductase (5-AR), the enzyme that lowers intraprostatic dihydrotestosterone levels, could prevent prostate cancer. Inhibiting 5-AR was an attractive target for prostate cancer chemopre vention, and two large randomized, placebo-controlled cancer prevention trials were initiated to evaluate the effect of the FDA-approved 5-AR inhibitors However, both trials demonstrated a potential increased risk of high-grade disease. The FDA conducted a pathological reassessment of the trial data and detected an absolute increase of 0.7% and 0.5% in the incidence of highgrade cancers (Gleason score 8-10) with finasteride and dutasteride, respectively 4 . Because of this concerning finding, the FDA not only recommended against approval of 5-ARIs for the chemoprevention of prostate cancer but also modified both drug labels to include the observation that these drugs might increase the risk of developing highgrade prostate cancer 4 . The evidence at the time was inadequate to determine the effects of the drugs on prostate cancer-specific morbidity and mortality.
N e w s & V i e w s
However, two recently published epidemiology studies have revisited the prostate-cancer-preventive properties of these agents and bring into question the original concerns regarding the increased incidence of high-grade disease. Unger and colleagues 5 investigated whether the protective effects of finasteride lasted after drug discontinuation and extended the median follow-up duration to 16 years. They linked the Medicare claims database with the PCPT clinical records beyond the 7-year follow-up point specified in the original study protocol to better understand the cancer outcomes. At the 16-year follow-up point, men treated with finasteride had a 21.1% decreased risk of prostate cancer compared with placebo, with no increased risk of prostate cancer for those who received finasteride suggesting that a relatively short treatment duration of 7 years with finasteride could reduce prostate cancer diagnoses in the long term 5 . In the second study, Wallerstedt and co-workers 6 investigated the safety of 5-ARI treatment for lower urinary tract symptoms in terms of the associated risk of prostate cancer. Using the registry in Sweden, they evaluated 23,442 men who research findings from Unger and colleagues 5 and Wallerstadt and co-workers 6 suggest there might be true long-term benefits of 5-ARIs in preventing prostate cancer. What remains to be addressed is whether the safety warning should be removed from 5-ARI labels, as the benefits of 5-ARI therapy might far outweigh any potential risks related to prostate cancer incidence. 
